We then treated the orthotopic xenografts daily with FIDAS-5 (40 mg per kg) or vehicle control, and observed that intraperitoneal injection of FIDAS-5 markedly inhibited the growth of xenografts (Fig. 5E and 5F) and conferred a significant survival benefit relative to the vehicle control (Fig. 5G), thus support that MAT2A inhibitor effectively suppresses GBM growth and enhances animal survival. The gene discussed is MAT2A; the disease is glioblastoma.